For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 4.24 million shares were traded. CLOV stock price reached its highest trading level at $3.61 during the session, while it also had its lowest trading level at $3.5.
Ratios:
To gain a deeper understanding of CLOV’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4.
Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 07 ’25 when Edwards Carladenise Armbrister sold 200,000 shares for $3.61 per share. The transaction valued at 722,000 led to the insider holds 273,227 shares of the business.
Priest Brady Patrick sold 75,000 shares of CLOV for $276,000 on Mar 06 ’25. The CEO of Home Care now owns 2,418,151 shares after completing the transaction at $3.68 per share. On Mar 06 ’25, another insider, Soares Karen, who serves as the General Counsel & Secretary of the company, sold 52,500 shares for $3.80 each. As a result, the insider received 199,500 and left with 1,299,663 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1834156160 and an Enterprise Value of 1612600064. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.34 while its Price-to-Book (P/B) ratio in mrq is 5.10. Its current Enterprise Value per Revenue stands at 1.177 whereas that against EBITDA is -36.159.
Stock Price History:
The Beta on a monthly basis for CLOV is 1.99, which has changed by 3.7549667 over the last 52 weeks, in comparison to a change of 0.101756096 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $4.87, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is -11.84%, while the 200-Day Moving Average is calculated to be 13.01%.
Shares Statistics:
It appears that CLOV traded 6.06M shares on average per day over the past three months and 4281200 shares per day over the past ten days. A total of 395.74M shares are outstanding, with a floating share count of 382.86M. Insiders hold about 25.06% of the company’s shares, while institutions hold 18.20% stake in the company. Shares short for CLOV as of 1741910400 were 13140400 with a Short Ratio of 2.17, compared to 1739491200 on 15327893. Therefore, it implies a Short% of Shares Outstanding of 13140400 and a Short% of Float of 3.19.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
